Brokerages Set Gain Therapeutics, Inc. (NASDAQ:GANX) Price Target at $7.86

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) have received a consensus rating of “Moderate Buy” from the eight ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $7.8571.

GANX has been the topic of a number of recent research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Gain Therapeutics in a research report on Wednesday, October 8th. Roth Capital reduced their price target on shares of Gain Therapeutics from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, August 13th. Maxim Group raised their price target on shares of Gain Therapeutics from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, October 7th. BTIG Research restated a “buy” rating and issued a $9.00 price target on shares of Gain Therapeutics in a research report on Wednesday, October 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Gain Therapeutics in a research report on Monday, October 13th.

Gain Therapeutics Trading Down 2.0%

Gain Therapeutics stock opened at $1.97 on Friday. The firm’s 50-day moving average is $1.84 and its 200-day moving average is $1.79. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.79 and a current ratio of 1.79. Gain Therapeutics has a 1 year low of $1.41 and a 1 year high of $2.81. The company has a market cap of $70.82 million, a P/E ratio of -3.13 and a beta of 0.11.

Gain Therapeutics (NASDAQ:GANX) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). On average, equities analysts expect that Gain Therapeutics will post -1 earnings per share for the current year.

Institutional Trading of Gain Therapeutics

Several hedge funds have recently bought and sold shares of GANX. Dauntless Investment Group LLC bought a new stake in Gain Therapeutics in the 1st quarter valued at about $240,000. Marshall Wace LLP lifted its position in Gain Therapeutics by 41.0% in the 2nd quarter. Marshall Wace LLP now owns 276,433 shares of the company’s stock valued at $498,000 after purchasing an additional 80,407 shares during the last quarter. Kovitz Investment Group Partners LLC bought a new stake in Gain Therapeutics in the 1st quarter valued at about $91,000. Finally, Geode Capital Management LLC lifted its position in Gain Therapeutics by 2.9% in the 2nd quarter. Geode Capital Management LLC now owns 290,462 shares of the company’s stock valued at $523,000 after purchasing an additional 8,251 shares during the last quarter. 11.97% of the stock is currently owned by institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.